Nutraceutical as Complementary Therapy in Major Depressive Disorder (MDD)
DOI:
https://doi.org/10.53089/medula.v13i3.630Keywords:
Major Depressive Disorders, Mechanism of Action, NutraceuticalAbstract
Major depressive disorder (MDD) is known as a type of major depression characterized by altered mood, impaired cognitive function, anhedonia (inability to be able to feel pleasure), vegetative disorders such as insomnia, and fatigue or anorexia. Major depressive disorder (MDD) is one of the most common mental disorders worldwide, as well as one of the most disabling. The current treatment is inadequate so that about two-thirds of those treated with first-line antidepressants do not achieve remission. A therapeutic approach using nutraceutical can improve the response to cases of resistance in antidepressants. Nutraceutical is used as the prevention and treatment of various diseases or neurological disorders without or minimal side effects. A therapeutic approach using nutraceutical can improve the response to cases of resistance in antidepressants by targeting neurobiological pathways associated with the pathophysiology of depression. The purpose of writing this article is to find out the nutraceutical that can be consumed as complementary therapies of major depressive disorder (MDD). The source search method is done through the Google Scholar and Pubmed search engines. The results of the search found several nutraceutical, namely Probiotics, Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs), Vitamin D, S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HRAL9 have antidepressant activity. Nutraceutical has the potential to be a complementary therapy in effective major depressive disorder (MDD) therapy.
References
Alvarez-Mon MA, Ortega MA, García-Montero C, Fraile-Martinez O, Monserrat J, Lahera G, dkk. Exploring the role of nutraceuticals in major depressive disorder (MDD): Rationale, state of the art and future prospects. Pharmaceuticals. 2021; 14(8): 1–32.
Gutiérrez-Rojas L, Porras-Segovia A, Dunne H, Andrade-González N, Cervilla JA. Prevalence and correlates of major depressive disorder: A systematic review. Brazilian Journal of Psychiatry. 2020; 42(6): 657–672.
Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: Challenges and strategies. Neuropsychiatric Disease and Treatment. 2020; 16: 221–234.
Sarris J, Byrne GJ, Stough C, Bousman C, Mischoulon D, Murphy J,dkk. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. Journal of Affective Disorders. 2019; 245: 1007–1015.
Chiu HF, Venkatakrishnan K, Wang CK. The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: A mini review. Journal of Traditional and Complementary Medicine. 2020; 10(5): 434–439.
Sarris J, Byrne GJ, Bousman C, Stough C, Murphy J, MacDonald P, dkk. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. European Neuropsychopharmacology. 2018; 28(10): 1126–1136.
Helal NA, Eassa HA, Amer AM, Eltokhy MA, Edafiogho I, Nounou MI. Nutraceuticals’ Novel Formulations: The Good, the Bad, the Unknown and Patents Involved. In Recent Patents on Drug Delivery & Formulation. 2019; 13 (2).
Sachdeva V, Roy A, Bharadvaja N. Current Prospects of Nutraceuticals: A Review. Current Pharmaceutical Biotechnology. 2020; 21(10): 884–896.
Karakula-Juchnowicz H, Rog J, Juchnowicz D, Łoniewski I, Skonieczna-Ydecka K, Krukow P, dkk. The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): A 12-week, randomized, double-blind, and placebo-controlled clinical study protocol. Nutrition Journal. 2019; 18(1): 1–13.
Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav. 2019; 0291:13–23.
Ho Y, Tsai Y, Kuo TBJ, Yang CCH. Effects of Lactobacillus plantarum PS128 on Depressive Symptoms and Sleep Quality in Self-Reported Insomniacs : A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. 2021; 13(8): 1–15.
Schaub A, Schneider E, Vazquez-castellanos JF, Schweinfurth N, Kettelhack C, Doll JPK. Clinical , gut microbial and neural effects of a probiotic add-on therapy in depressed patients : a randomized controlled trial. 2022: 1–10.
Reiter A, Bengesser SA, Hauschild A, Fellendorf FT, Platzer M, Färber T, dkk. Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder — Preliminary Results of the PROVIT Study. 2020; 1: 1–17.
Reininghaus EZ, Platzer M, Kohlhammer-dohr A, Hamm C, Mörkl S, Bengesser SA, dkk. PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial. 2020; 12(11): 3422.
Luo XD, Feng JS, Yang Z, Huang QT, Lin JDA, Yang B, dkk. High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: A network meta-analysis. BMC Psychiatry. 2020; 20(1): 1–8.
Wolters M, Haar AVD, Baalmann A, Wellbrock M, Rach S, Heise TL. Effects of n-3 Polyunsaturated Fatty Acid Supplementation in the Prevention and Treatment of Depressive Disorders — A. 2021
Menon FV. Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials. 2019; 65(2): 74–80.
Alberto S, Paolo M, Ivano M, Rinaldo P, Andrea P, Roberto C, dkk. Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. 2020; 22(4).
Lombardi VC, De MKL, Subramanian K, Nourani SM, Dagda RK, Delaney SL, dkk. Nutritional modulation of the intestinal microbiota: future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease. Journal of Nutritional Biochemistry. 2018; 61: 1–16.
Chudzik A, Orzyłowska A, Rola R, Stanisz GJ. Probiotics, prebiotics and postbiotics on mitigation of depression symptoms: Modulation of the brain–gut–microbiome axis. Biomolecules. 2021; 11(7).
Strandwitza P. Neurotransmitter modulation by the gut microbiota. Physiology & Behavior. 2018; 176(1): 139–
Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, dkk. Omega-3 fatty acids for depression in adults. Cochrane Database of Systematic Reviews. 2021; (11).
Guu T, Sarris J, Matsuoka YJ, Belmaker RH, Pariante C. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychotherapy and Psychosomatics. 2020; 89(6): 406–407.
Borsini A, Nicolaou A, Camacho-Muñoz D, Kendall AC, Di Benedetto MG, Giacobbe J, dkk. Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis. Molecular Psychiatry. 2021; 26(11): 6773–6788.
Bahrami A, Mazloum SR, Maghsoudi S, Soleimani D, Khayyatzadeh SS, Arekhi S, dkk. High Dose Vitamin D Supplementation Is Associated With a Reduction in Depression Score Among Adolescent Girls: A Nine-Week Follow-Up Study. Journal of Dietary Supplements. 2018; 15(2): 173–182.
Sabir MS, Haussler MR, Mallick S, Kaneko I, Lucas DA, Haussler CA, dkk. Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines. Genes and Nutrition. 2018; 13(1): 1–11.
Cuomo A, Beccarini CB, Bolognesi S, Goracci A, Koukouna D, Rossi R, dkk. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): A clinician-oriented systematic review. Annals of General Psychiatry. 2020; 19(1): 1–7.
Hitoshi S, Linda C, Audrey T, Price, George P, Christina MD, dkk. Dose Increase of S-Adenosyl-Methionine and Escitalopram in a Randomized Clinical Trial for Major Depressive Disorder. J Affect Discord. 2021; 34(5): 737–748.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
